PROSTATE DISEASE
BPH AND PROSTATITIS – DIAGNOSIS AND MANAGEMENT

BENIGN PROSTATIC HYPERPLASIA (BPH)

- BPH is the non-cancerous enlargement of the prostate gland
- Whilst not normally life threatening, BPH can impact considerably on quality of life

The GP’s role
- GPs are typically the first point of contact for men with BPH
- The GP’s role in the management of BPH includes clinical assessment, treatment, referral and follow-up

Diagnosis

Medical History
- Lower urinary tract symptoms (LUTS)

Urinary symptoms of BPH
- Hesitancy
- Weak and poorly directed stream
- Straining
- Post-urination dribble or irregular stream

Note: Some men with BPH may not present with many or any symptoms of the disease.

Symptom score
- Evaluation of symptoms contributes to treatment allocation and response monitoring
- The International Prostate Symptom Score (IPSS) questionnaire is recommended

Physical examination
- Digital rectal examination (DRE): can estimate prostate size and identify other prostate pathologies
- Basic neurological examination
- Perianal sensation and sphincter tone
- Bladder palpation
- Caliber of the urethral meatus

Investigations
- Urine analysis: midstream urine: microscopy, culture and sensitivity (MC&S)
- Prostate specific antigen (PSA) levels: while PSA levels are mostly used as a marker of prostate cancer, PSA levels can be elevated as a result of non cancerous prostate disease (BPH and prostatitis)

PSA LEVELS FOR DIFFERENT AGE GROUPS OF WESTERN MEN

<table>
<thead>
<tr>
<th>Age range years</th>
<th>Serum PSA (ng/ml) median</th>
<th>Serum PSA (ng/ml) upper limit of normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>40-49</td>
<td>0.65</td>
<td>2.0</td>
</tr>
<tr>
<td>50-59</td>
<td>0.85</td>
<td>3.0</td>
</tr>
<tr>
<td>60-69</td>
<td>1.39</td>
<td>4.0</td>
</tr>
<tr>
<td>70-79</td>
<td>1.64</td>
<td>5.5</td>
</tr>
</tbody>
</table>

Management

Treatment
- Watchful waiting: for mild or low impact symptoms
- Optimise through reassurance, education, periodic monitoring and lifestyle modifications

Medical therapy: for moderate to severe symptoms
- α-blockers
  - Suited to patients with moderate/severe LUTS
- All α1-blockers (Alfuzosin, Tamsulosin, Terazosin, Prazosin) have a similar clinical efficacy (side-effect profiles favour Tamsulosin)
- 5α-reductase-inhibitors
  - Including Dutasteride and Finasteride
  - Suited to patients with moderate/severe LUTS and enlarged prostates (>30–40ml)
  - Finasteride reduces prostate volume by 20–30% and seems to have similar clinical efficacy
- Combination therapy: α-blocker with 5α-reductase-inhibitor
  - Has been shown to be more beneficial and durable than the monotherapy of either substance

Surgical therapy: for severe or high impact symptoms
- Transurethral resection of the prostate (TURP) for prostates 30–80ml
- Transurethral incision of the prostate (TUIP) for prostates <30ml and without middle lobe
- Open prostatectomy or TURP for those >80ml
- Laser ablation or resection of BPH available in specific surgical centres. Laser surgery regarded as equivalent efficacy to TURP
- Other options also available

Specialist referral
- Indicators for referral to a Urologist
  - The patient’s symptoms become more serious: their symptom score moves into the ‘severely symptomatic’ category
  - The patient’s symptoms significantly interfere with their quality of life – score of 5 ‘unhappy’ or 6 ‘terrible’ on the IPSS
  - After an episode of urinary retention, urinary infection, haematuria
  - No response to treatment
  - A risk of prostate cancer exists
  - Post void residual urine on ultrasound assessment >100ml

Other PSA tests:
- PSA velocity or doubling time: if the PSA level doubles in 12 months it may indicate prostate cancer or prostatitis.
- An elevated PSA and a stable velocity suggests BPH
- Free-to-total PSA ratio: high ratio (>25%) suggests BPH; low ratio (<10%) suggests prostate cancer

Refer to Early Detection of Prostate Cancer guideline (TCCQ) at www.andrologyaustralia.org

 Optional investigations (usually by the Urologist)
- Uroflowmetry (Specialist only)
- Pressure-flow study
- Endoscopy

Refer to Clinical Comprehensive Guide 7

www.andrologyaustralia.org
Follow-up
It is appropriate for the GP to monitor and follow-up a patient with respect to all the treatment modalities. If a specialist is involved, he/she may refer the patient back to the GP for ongoing follow-up as directed.

Clinical notes: Men who have had TURP remain at risk for prostate cancer and need routine prostate cancer checks.

Recommended follow-up timeline after BPH treatment

<table>
<thead>
<tr>
<th>Treatment modality</th>
<th>First year after treatment</th>
<th>Annually thereafter</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>6 weeks</td>
<td>12 weeks</td>
</tr>
<tr>
<td>Watchful waiting</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>5α-reductase inhibitors</td>
<td>X</td>
<td>✓</td>
</tr>
<tr>
<td>α-blockers</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Surgery or minimal invasive treatment</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

PROSTATITIS

- Prostatitis is an inflammation of the prostate gland
- It can be a result of bacterial or non-bacterial infection
- Acute bacterial prostatitis, the least common form, can be life threatening if the infection is left untreated
- Whilst not normally life threatening, prostatitis can impact considerably on men's quality of life

The GP’s role
- GPs are typically the first point of contact for men with prostatitis
- The GP’s role in the management of prostatitis includes clinical assessment, treatment, referral and follow-up

Diagnosis

<table>
<thead>
<tr>
<th>Medical history</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Urinary symptoms</td>
<td>Pain</td>
</tr>
<tr>
<td>Symptoms of prostatitis</td>
<td></td>
</tr>
<tr>
<td>Dysuria – painful urination</td>
<td>Perineal pain</td>
</tr>
<tr>
<td>Urgent need to urinate</td>
<td>Chills and/or fever</td>
</tr>
<tr>
<td>Frequent urination</td>
<td>Muscular pain</td>
</tr>
<tr>
<td>Painful ejaculation</td>
<td>General lack of energy</td>
</tr>
<tr>
<td>Lower back pain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investigations</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Digital rectal examination (DRE): prostate tenderness or swelling</td>
<td></td>
</tr>
<tr>
<td>Prostate specific antigen (PSA) levels: elevated PSA levels</td>
<td></td>
</tr>
<tr>
<td>- PSA velocity: if the PSA level doubles in 12 months it may indicate prostate cancer or prostatitis</td>
<td></td>
</tr>
<tr>
<td>Urine analysis:</td>
<td></td>
</tr>
<tr>
<td>- First pass urine: Chlamydia urine PCR test</td>
<td></td>
</tr>
<tr>
<td>- Midstream urine: MCRS</td>
<td></td>
</tr>
</tbody>
</table>

Management

Treatment
- There are several therapeutic options available. Evidence for benefits of these treatment options is limited; however, they may be trialed with the patient
- With respect to management by the Specialist, use of the following forms of treatment will vary according to the individual, their condition and the stage of their treatment
- Most patients at some stage in their treatment however will have antibiotic therapy

Bacterial prostatitis (acute and chronic) can be treated using antibiotics. Once diagnosed, rapid treatment is essential to avoid further complications. Chronic nonbacterial prostatitis (chronic pelvic pain syndrome) causal treatment is difficult and cure is often not an option. Treatment focus is on symptom management, to improve quality of life.

Medication options
- Antibiotics (not all antibiotics penetrate the prostate glands)
  - Recommend: Norfloxaclin, Ciprofloxaclin, Trimethoprim, Sulphamethoxazole/Trimethoprim, Erythromycin, Gentamicin
  - Young men with confirmed Chlamydia prostatitis: Doxycycline (Vibramycin®)
  - Muscle relaxants: Diazepam, Baclofen
  - Analgesics
  - Non-steroidal anti-inflammatory drugs
  - 5α-reductase-inhibitors: Finasteride

Surgical options*
- Transurethral incision of the bladder neck
- Transurethral resection of the prostate
* Surgery has a very limited role and requires an additional, specific indication e.g. prostate obstruction, prostate calcification

Other options
- Lifestyle changes: avoid activity that involves vibration or trauma to the perineum e.g. bike riding, tractor driving, long-distance driving, cut out caffeine, spicy foods, alcohol, avoid constipation
- Pelvic floor relaxation techniques
- Prostate massage
- Supportive therapy: biofeedback, relaxation exercises, acupuncture, massage therapy, chiropractic therapy and meditation
- Heat therapy

Specialist referral
Indicators for referral to a Urologist:
- When the GP is not confident in managing the condition
- If the GP is concerned there are other potential diagnoses, particularly prostate or bladder cancer
- Those who do not respond to initial first-line therapy such as antibiotics and/or α-blockers. For these patients, more invasive investigations, such as cystoscopy and transrectal prostate ultrasound scan, are commonly considered necessary

Follow-up
- The need for specialist follow-up depends on the patient’s progress
- Most specialists will refer back to the GP to monitor the progress of the patient
- The specialist will seek re-referral if the patient’s progress is not appropriate
- A GP can re-refeer if they do not feel comfortable in managing a relapse

For references and other guides in this series visit www.andrologyaustralia.org
Acknowledgement: this guide is based on the EAU guidelines (2003 & 2004)